COMPASS® receives FDA clearance and is launched

COMPASS® receives FDA clearance and is launched

RaySearch Laboratories AB (publ.) and IBA (Ion Beam Applications S.A.: Reuters
IBAB.BR and Bloomberg IBAB.BB) announced today that the new dosimetry solution
COMPASS® has received 510(k) clearance by the FDA and that it has been launched
on the worldwide market through IBA's business unit IBA Dosimetry.

COMPASS® is a state-of-the-art solution for quality assurance in radiotherapy
that has been developed in joint cooperation between IBA Dosimetry and RaySearch
Laboratories AB. It will enable the medical staff to measure and reconstruct the
3D radiation dose that was actually delivered to the patient every day during
the course of treatment. This is highly valuable, particularly in advanced
IMRT/IGRT treatments that aim to maximize the effective dose delivered to the
tumor whilst sparing the surrounding healthy tissue.

COMPASS® will increase the safety of radiation therapy as it provides a truly
independent online analysis of both the accuracy of the planned treatment as
well as the dose delivered to the patient. 

“The COMPASS® FDA clearance and market launch is the culmination of two years of
joint effort with RaySearch Laboratories to design this novel dosimetry solution
that will allow radiotherapy departments to cope with the highest treatment
accuracy and reliability standards”, said Pierre Mottet, Chief Executive Officer
of IBA. “We are excited to be the first company in the world to propose such an
online dosimetry solution that will increase treatment efficiency and save
lives”, added Mr. Mottet.

“The combination of our expertise in advanced radiotherapy software and IBA
Dosimetry's world leading dosimetry expertise, has been the ideal foundation for
creating this revolutionary product”, said Johan Löf, Chief Executive Officer of
RaySearch. “In addition to improving the precision, COMPASS® has the potential
to significantly speed up the quality assurance process, which will enable the
clinics to spend more time on treating patients and simultaneously improve
safety.”


ABOUT IBA DOSIMETRY
IBA Dosimetry is a fully owned division of IBA. With more than 30 years
experience, it provides sophisticated and customized high-end dosimetry and
quality assurance solutions for use in hospitals and by industry partners across
the world. Access to national and international research partners, as well as
in-house research and design activities are the foundation of successful and
reliable products for a wide range of dosimetry applications in radiotherapy and
radiodiagnostics.
Website: http://www.iba-dosimetry.com 

ABOUT IBA
IBA delivers solutions of exceptional precision in the fields of cancer
diagnosis and therapy. The company also provides sterilization and ionization
solutions to improve the hygiene and safety of everyday life. IBA is listed on
the pan-European stock exchange EURONEXT and belongs to the BelMid index.
Website: http://www.iba-worldwide.com
ABOUT RAYSEARCH
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners such as
Philips, Varian Medical Systems, Nucletron, IBA Dosimetry and TomoTherapy. Eight
products have been released to date and RaySearch's software is used at over
1,200 clinics in more than 30 countries. In addition, existing license
agreements cover more than 15 other products that are scheduled to be launched
in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska
Institutet in Stockholm and the company is listed in the MidCap segment on the
OMX Nordic Exchange Stockholm. 

For more information about RaySearch, please visit www.raysearchlabs.com.


FOR FURTHER INFORMATION, CONTACT:

IBA
Paul-Emmanuel Goethals
Director, Corporate Business Development & Investor Relations 
Telephone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com

RAYSEARCH
Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com